BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants Not Receiving Other Complement Inhibitor Therapy
Trial details
- Registry ID
- NCT05116787
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants Not Receiving Other Complement Inhibitor TherapyNCT05116787 | BioCryst Pharmaceuticals | Phase 2 | Terminated | 2023-09-18Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |